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The Fc-a receptor (FcaR/CD89) is involved in IgA complex
formation and may affect the development of IgA
nephropathy (IgAN). In this study, we tested the genetic
variations of the CD89 gene in relation to disease
susceptibility in IgAN and the expression of soluble CD89
(sCD89) in sera of patients with IgAN and in controls. There
was a significant difference between the levels of sCD89–IgA
complexes, measured by sandwich enzyme-linked
immunosorbent assay (ELISA), in 177 patients with IgAN with
and without disease progression at the time of first diagnosis.
No such difference was found in 42 patients with other renal
diseases. The patients with IgAN without disease progression
had stable but high levels of sCD89 over 5–15 years of follow-
up in contrast to stable but low levels of sCD89 in the disease
progression group. Moreover, levels of sCD89 complexes
were correlated with one of the five CD89 genetic variants in
212 patients with IgAN and 477 healthy Caucasians; the
single-nucleotide polymorphism (SNP) rs11084377 was
significantly associated with a lower expression of sCD89.
However, no association between CD89 gene polymorphisms
and susceptibility to IgAN was detected. Thus, we found an
association between the levels of sCD89–IgA complexes in
serum and the severity of IgAN, and a possible genetic
component in regulating the production or expression
of sCD89.
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The Fc-a receptor (FcaRI/CD89) is a type I receptor glycoprotein
expressed on myeloid cells, with known capability of high affinity
binding of immunoglobulin A (IgA).1 In addition, the existence
of the soluble CD89 (sCD89) molecule has been detected both
in vitro, in supernatants on activation of peripheral blood
cells by enzyme linked immunosorbent assay (ELISA)2 and
in vivo, in human plasma, using western blotting.3 A 30 kDa
sCD89 molecule has been demonstrated to be tightly bound
to IgA and the CD89–IgA complex has been detected in
relatively high concentrations (mean value 1900 ng/ml) in
human plasma using semiquantitative dot blotting.3 Further-
more, as CD89–IgA complex is detectable in the circulation3,
it has been suggested that CD89 might contribute to the
formation of polymeric serum IgA. However, no method for
quantitation of sCD89 in human plasma or serum has
previously been described.
The FCAR gene encodes for the synthesis of FcaRI/CD89
and is located on human chromosome 19q13.4 (OMIM
147045) close to killer cell immunoglobulin-like receptor and
leukocyte immunoglobulin-like receptor (also known as ILT
and LIR) gene clusters. The FCAR gene has five exons and
generates up to 10 different transcripts, several of which
contain the transmembrane domain from exon 5. The
function of its products or their expression might be
influenced by genetic variances, such as single nucleotide
polymorphisms (SNPs). There are two SNPs in the promoter
of the FCAR gene (311T/G and 142T/C) that are
important for the promoter activity in a luciferase reporter
gene assay.4 These SNPs have been shown to be in association
with chronic hepatitis C in a Japanese population,5 but were
not reported to be high risk factors in allergic asthma.6
According to the HapMap database there are two relatively
small recombination blocks, one upstream of the gene within
the promoter and the first two exons, and the other within
the last exon.
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IgA nephropathy (IgAN) is the most common form of
primary glomerulonephritis, particularly in Western and
Asian countries.7,8 Familial clustering studies suggest linkage
of specific loci on chromosomes 6q22-q23, 4q26-31 and
17q12-22 with both susceptibility and progression of
IgAN.9–11 The polygenic complex nature of IgAN is broadly
accepted, but very little is known about the specific genetic
risk factors. Previously published data on the association of
variations in the FCAR gene suggest the importance of FcaR
expression in IgAN patients12 and on FcaR binding ability.13
Interestingly, human FCAR transgenic mice develop sponta-
neous IgAN.14 Our aim was to investigate the genetic
influence of FCAR on the susceptibility and progression of
IgAN with emphasis on the expression of sCD89 in plasma
and its quantitation.
RESULTS
Detection of 30 kDa CD89 protein in plasma by western
blotting
To prove the presence of sCD89 in plasma of IgAN patients
and healthy individuals western blotting was used. A 30 kDa
protein band representing sCD89 was visualized in plasma
samples of all tested individuals (Figure 1) using two
different mouse monoclonal anti-CD89 antibodies (desig-
nated MIP8 and A3) and a polyclonal rabbit anti-CD89
antibody, all described in Materials and Methods. Both free
sCD89 (MIP 8) and sCD89 bound to IgA (A3) can be
detected in this way, although no free CD89 was found in the
plasma samples and all reactivity was detected within the
CD89–IgA complex (data not included).
Quantitation of sCD89 in sera of IgAN patients and healthy
controls
With the finding from western blotting as background, an
ELISA method was developed using one monoclonal anti-
body (A3) specific for CD89 as capture antibody and a
polyclonal anti-IgA antibody for detection of CD89–IgA
complexes.
Detectable levels of CD89–IgA complex in sera of IgAN
patients and healthy controls were recorded in varying levels
from 0.5 to 114% of a reference. The reference was a serum
sample from one IgAN patient with a rather high level of
sCD89, selected from western blot experiments. Distribution
of sCD89 in the circulation of 115 healthy individuals has an
approximate binomial shape with median (interquartile; 6.4
(2.5–27.2)). The majority of the individuals (n¼ 78, 67.8%)
had a sCD89 o20 relative units and 37 individuals (32.2%)
exceeded 20 relative units.
There was no significant difference between the sCD89
levels in the whole group of IgAN patients compared with the
healthy control group. Furthermore, the serum levels of
sCD89 were similar in the disease control group in
comparison with the whole IgAN patient group. We found
no significant correlations between the level of sCD89 and
estimated glomerular filtration rate (GFR), P-value for the
two-tailed Pearson’s correlation coefficient¼ 0.15, or between
sCD89 levels and proteinuria, the Spearman’s correlation
coefficient¼ 0.2.
The level of sCD89 complex is associated with the severity
of IgAN
To investigate a possible association between sCD89 levels
and disease severity in IgAN patients two groups were
compared, IgAN progression (n¼ 17) and non-progression
group (n¼ 92). Disease progression was defined as either
doubling of serum creatinine during the follow-up period (at
least 1 year of observation) or reaching stage 5 of chronic
kidney disease (GFRo15ml per min per 1.73m2). The
remaining patients with available clinical data, who did not
reach doubling of serum creatinine during follow-up or had
GFR X15ml per min per 1.73m2 at last observation, were
classified as the IgAN non-progression group. The disease
severity criteria were defined as described in the Materials
and Methods section. There was a significant difference in
levels of sCD89 between the two groups (P¼ 0.002), with
higher levels in the non-progression group (median 13.12
(2.81–32.83)), compared with the progression group (median
2.9 (1.82–4.82)), (Figure 2).
The disease control group, which was matched with IgAN
group by sex, gender, serum creatinine and proteinuria levels,
consisted of 42 patients who had undergone renal biopsy
showing different forms of glomerular disease (lupus
nephritis, minimal change disease, focal and segmental
glomerulosclerosis). In contrast to the findings in the IgAN
group, there was no significant difference in sCD89 levels in
the disease control group (n¼ 42) comparing patients with
disease progression (n¼ 20) to those without progression
(n¼ 22; P¼ 0.326).
The level of sCD89 was also analyzed in 62 serum samples
from seven IgAN patients (four with disease progression and
three without progression) who had undergone repeated
blood sampling during 5–15 years of follow-up. Interestingly,
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Figure 1 |Western blot for detection of CD89 (after SDS
electrophoresis). Lanes 1, 2, and 4: plasma samples; lane 3:
molecular weight marker; lane 5: recombinant CD89. Western blot
of plasma of two immunoglobulin A nephropathy patients, one
control subject, and rCD89, is shown, using the polyclonal rabbit
anti-CD89 pIDEAE as primary antibody and goat anti-rabbit
immunoglobulin A*alkaline phosphatase conjugate as the
secondary detection antibody.
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all three IgAN patients without progression had stable and
high levels of sCD89 during the follow-up period in contrast
to continuous low levels of sCD89 in the four patients with
disease progression (Figure 3).
Gene polymorphism in FCAR is not associated with
susceptibility to or severity of IgAN
There was no significant association with IgAN and the
investigated SNPs (Table 1). No significant differences
regarding gender were found in the investigated study
population. Haplotype analysis based on five SNPs resulted
in 8 out of 32 expected haplotypes: GCGAA, GCAGA,
ACAGG, GTAGA, ACAGA, ACGAA, GTGAA, GCAGG with
frequency 41%, but none demonstrated a significant
association with IgAN (Table 2). No significant differences
in genotype frequencies in either the codominant model or
the dominant/recessive model were observed among the
different severity groups with or without stratification for
gender (data not included).
Correlations between the sCD89–IgA complex levels and
FCAR genotypes
To address the possible influence of genetic variations on
production of sCD89, sCD89–IgA complex levels were
analyzed in individuals with different FCAR genotypes. We
did not record any disease-specific effects in our study
population. However, in the combined group, using a
dominant/recessive model, it appeared that one of the SNP
(rs11084377) was associated with lower production of sCD89
in the G dominant model (P¼ 0.04, Mann–Whitney Test)
(Figure 4). This marker is in close proximity to the
alternative exon 2 in the FCAR gene structure, which is part
of the common domain for Ig superfamily proteins.
DISCUSSION
The most important finding in our study is the significant
association between the levels of soluble Fc-a receptor
(sCD89)–IgA complex in sera of IgAN patients and the
progression of IgAN. In a disease control group of patients
with other forms of glomerulonephritis, who had similar
renal function and proteinuria as the IgAN group, no
correlation to disease progression was observed. In addition,
serum levels of sCD89 remained stable and low in IgAN
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Figure 2 |Distribution of the levels of soluble CD89 (sCD89)
complex in serum of control group and immunoglobulin A
nephropathy patients. There was a significant difference in
sCD89 levels in immunoglobulin A nephropathy patients with and
without disease progression (P¼ 0.002, Mann–Whitney Test).
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Figure 3 | Soluble CD89 (sCD89) levels in immunoglobulin A nephropathy (IgAN) patients with and without disease progression
during a long-term follow-up.
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patients with disease progression and continuously high in
IgAN patients without progression, during a follow-up
period of 5–15 years. We first developed an indirect ELISA
method for measuring the levels of sCD89 in human sera
through detection of IgA in the sCD89–IgA complex. The
other important finding is the absence of an association of
IgAN with variants of the FCAR gene, as well as the finding
of a possible influence of FCAR gene polymorphism on
production of sCD89. A considerable variation in levels of
sCD89 in the circulation of patients with IgAN was also
observed. In FCAR transgenic mice IgA immune complexes
have been demonstrated to arise spontaneously in glomerular
deposits. As this pathological condition is also seen in IgAN
patients, it may be possible that sCD89 is also involved in
human disease.
We selected several gene variations for this analysis on the
basis of our previous experience in genotyping of different
gene loci. As even a small deviation from linkage disequili-
brium may be important for detection of the association, we
chose SNPs distributed all over the gene region and flanking
regions. As is evident from our results, a recombination
inside the FCAR gene is rare in the Caucasian population: out
of 32 expected haplotypes, we recorded 8 that were common
for the investigated population. This is evidence of strong
linkage disequilibrium in this region, which in theory
increases the chance for detection of an association by
haplotype analysis (Figure 5).
However, an association with susceptibility to IgAN was
not detected for selected common variations in the FCAR
gene. For the univariate allelic test there was only a 80%
power to detect signals with odds ratio 1.9 or higher in our
study population. As the genetic risk for a complex disease is
expected to be low, our genetic association study may
Table 1 | Genotype frequencies of FCAR gene polymorphisms in IgAN patients in the dominant/recessive models
SNP Dominant/recessive model v2 P-valuea
FCAR rs11084377 Total AA AG+GG
Group n=665 Control 462 43 (9.3%) 419 (90.7%) 3.69 0.05
Patient 203 10 (4.9%) 193 (95.1%)
FCAR rs4806605 Total CC CT+TT 0.06 0.86
Group n=679 Control 469 306 (65.2%) 163 (34.8%)
Patient 210 135 (64.3%) 75 (35.7%)
FCAR rs10402324 Total AA AG+GG 1.59 0.21
Group n=676 Control 465 207 (44.5%) 258 (55.5%)
Patient 211 83 (39.3%) 128 (60.7%)
FCAR rs1865097 Total AA AG+GG 2.46 0.12
Group n=677 Control 466 47 (10.1%) 419 (89.9%)
Patient 211 30 (14.2%) 181 (85.8%)
FCAR rs16986050 Total AA AG+GG 0.04 0.85
Group n=670 Control 474 318 (67.1%) 156 (32.9%)
Patient 196 133 (67.9%) 63 (32.1%)
Abbreviations: FCAR, Fc-a receptor; IgAN, immunoglobulin A nephropathy; SNP, single nucleotide polymorphism.
aNon-corrected.
Table 2 | Haplotype frequencies of FCAR gene polymorphisms in IgAN patients and healthy controls
Block Haplotype frequency Control/case ratio counts Control/case frequencies v2 P-valuea
GCGAA 0.265 233.9:704.1, 124.9:293.1 0.249, 0.299 3.623 0.06
GCAGA 0.239 235.8:702.2, 88.7:329.3 0.251, 0.212 2.440 NS
ACAGG 0.168 159.7:778.3, 67.6:350.4 0.170, 0.162 0.153 NS
GTAGA 0.16 146.6:791.4, 70.0:348.0 0.156, 0.167 0.266 NS
ACAGA 0.074 73.2:864.8, 27.8:390.2 0.078, 0.067 0.553 NS
ACGAA 0.044 41.6:896.4, 18.6:399.4 0.044, 0.044 0 NS
GTGAA 0.028 25.3:912.7, 12.1:405.9 0.027, 0.029 0.042 NS
Abbreviations: IgAN, immunoglobulin A nephropathy; NS, not significant.
aNon-corrected.
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Figure 4 | The levels of soluble CD89 (sCD89) in serum of
individuals with different genotypes (single nucleotide
polymorphism rs11084377) (P¼ 0.04, Mann–Whitney Test).
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represent a type II error. On the other hand, the haplotype
analysis suggests that there is a low, if any, probability of less
common genetic variation, which may be important for the
disease.
In this study, we developed a new method for detection
the of sCD89–IgA complex in human serum. Several previous
attempts from other groups to quantify sCD89 directly in
serum or plasma have failed, probably because of the fact that
all sCD89 molecules are tightly bound to IgA within the
CD89–IgA complexes and only a minor portion of the sCD89
molecule is exposed for antibody recognition. Alternatively,
when these complexes were dissociated in vitro by strong
detergents such as SDS, this reaction in solution was hindered
because of antibody denaturation. Western blotting was
effective, but is however not an accurate quantitative method.
We resolved the problem by the detection of sCD89–IgA
complexes instead of the free sCD89 molecules through
indirect detection of this complex with antibodies against
IgA, whereas the specificity of the reaction was ensured by
capturing the sCD89 from the serum with a specific
monoclonal anti-CD89 antibody. This method could be used
for detection of circulating sCD89 in serum/plasma in
different pathological conditions.
One concern regarding the detection of this complex is
related to its composition. We based our analysis on the
assumption of its relative homogeneity (one IgA molecule
bound to one sCD89 molecule). In fact, if there are
differences in IgA/CD89 ratios in different individuals the
measurements may be inaccurate. However, to our knowl-
edge, there was no indication for such heterogeneity.
Our data also suggest the influence of FCAR (CD89) gene
polymorphisms in the regulation of production and/or
expression of sCD89, which may relate to splicing mechan-
isms. This has to be proven in independent experiments
because of the multiple testing in our study and relatively low
effect value.
We can only speculate regarding possible mechanisms
related to sCD89–IgA complexes influence on progression of
IgA. There are at least two possible explanations. One might
speculate that these complexes are more ‘sticky’, precipitate at
kidney, disturb its function and are less represented in the
circulation in IgAN patients with disease progression. Another
option is that circulating complexes are not pathogenic by itself,
but glomerular IgA deposits occur as a reflection of low levels
of sCD89, which cause an unusual reaction of IgA with other
proteins in glomeruli and precipitation of IgA there. These issues
might be addressed in future studies.
Although we did not find a significant association with
susceptibility of IgAN for the investigated SNPs, we here
report an association between the serum levels of sCD89–IgA
complex and the severity of IgAN as a novel marker for
disease progression.
MATERIALS AND METHODS
Patients and healthy subjects
A total of 212 unrelated patients (146 males and 66 females), mean
age 39±14 (range 17–77 years) with biopsy-proven IgAN and 477
healthy Swedish Caucasians (321 males and 156 females), mean age
45±13 (range 18–80 years), matched by gender, were included in
the study. The patients were recruited from the Department of
Nephrology at the Karolinska University Hospital (n¼ 117), Danderyd
Hospital (n¼ 31), Sko¨vde Hospital (n¼ 36) and Linko¨ping Hospital
(n¼ 28), representing a population mainly resident in the central part
of Sweden. Patients with Henoch-Scho¨nlein purpura and patients
with concomitant renal diagnosis were not included in the IgAN
patient group.
The sera from IgAN patients for comparison between the groups
were collected within few days from the first diagnosis and biopsy.
In all, 42 patients who had undergone renal biopsy and who had
other forms of glomerular disease, namely lupus nephritis, minimal
change disease or focal and segmental glomerulosclerosis were
selected as the disease control group. They were matched by sex,
gender, serum creatinine and proteinuria levels with IgAN patients.
In seven IgAN patients (three without disease progression and
four with progression) with serum samples collected longitudinally
for 5–15 years of follow-up, sCD89 was analyzed at different time
points in a total of 62 samples.
All included individuals gave informed consent and the study
was approved by the Ethics Committee of the Karolinska University
Hospital, Stockholm, Sweden.
Disease severity
A total of 109 IgAN patients from the Karolinska University
Hospital who had been followed for up to 15 years since renal biopsy
were investigated for the correlation between genotype and disease
severity. GFR was estimated from yearly serum creatinine measure-
ments using the Modification of Diet in Renal Disease equation.15
To investigate the correlation between genotype and disease severity
the following criteria were used: IgAN progression (n¼ 17) was
defined as either doubling of serum creatinine during the time of
follow-up (at least 1 year of observation) or reaching stage 5 of
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Figure 5 | The linkage disequilibrium in FCAR gene for five
investigated single nucleotide polymorphisms, r2-value.
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chronic kidney disease (GFRo15ml per min per 1.73m2). The
remaining patients with available clinical data, who did not reach
doubling of serum creatinine during follow-up or had GFRX15ml
per min per 1.73m2, were classified as the IgAN non-progression
group (n¼ 92). In the disease control group (n¼ 42), using the
same criteria for disease severity, 22 patients were placed in the non-
progression group and 20 patients in the progression group.
Antibodies
Two commercial monoclonal mouse anti-human CD89 antibodies,
clones MIP8a and A3 (Abcam, Cambridge, UK), with different
specificities for CD89 were used in western blotting and/or ELISA.
Antibody MIP8a is directed against an epitope involved in CD89
binding to IgA, whereas the A3 antibody recognizes CD89
independently of IgA binding. A polyclonal rabbit anti-human
CD89 IgG antibody, designated pIDEA2 was used. For detection,
several polyclonal antibodies conjugated to alkaline phosphatase
(AP) were used in different test systems: Rabbit anti-mouse IgG
(Abcam), Goat anti-mouse IgG (Southern Biotech, AL, USA); Goat
anti-rabbit IgG (F(ab)2) (Sigma-Aldrich, St Louis, MI, USA) and
Rabbit anti-human IgA (DAKO, Glostrup, Denmark).
Recombinant sCD89 (rCD89) protein was used as a positive
control in western blotting experiments.2
Electrophoresis and western blotting
Separation of plasma proteins from IgAN patients, controls and
rCD89 was performed using 14% Tris-glycine polyacrylamide gels
(Invitrogen Life Technologies, Carlsbad, CA, USA) at 125 V and
35mA for 1.5 h in a NOVEX system (Invitrogen Life Technologies).
Plasma samples and rCD89 were diluted in phosphate-buffered
saline (PBS), pH 7.2 and loaded into gels with either reducing
sample buffer (50% Tris-glycine SDS sample buffer 2 concentra-
tion (Invitrogen Life Technologies) mixed with 35% dH2O and 15%
mercaptoethanol (Sigma-Aldrich) or non-reducing sample buffer
(50% Tris-glycine SDS sample buffer 2 concentration mixed 1:1
with water), boiled at 99 1C for 9min and centrifuged to eliminate
precipitate. A volume of 30 ml of plasma diluted 1:30 and 30 ml of
rCD89 at a final concentration of 75 mg/ml were loaded into the gel
together with 30 ml of the broad range protein molecular weight
marker (SeeBlue Plus2 Pre-Stained Standard, Invitrogen Life
Technologies). After electrophoresis, the gel was either stained by
Coomassie blue for total protein staining or the proteins were
transferred onto nitrocellulose membrane (0.45 nm, Invitrogen Life
Technologies) for western blotting in a NOVEX transfer module
(Invitrogen Life Technologies). After the transfer the nitrocellulose
membranes were blocked with 5% gelatin from cold water fish skin
(Sigma-Aldrich) in PBS for 2 h at 37 1C, followed by washing with
PBS with 0.05% Tween 20 (PBS-T) (Merck Eurolab AB, Stockholm,
Sweden) (PBS-T) and incubation with one of the anti-CD89
antibodies at the time: MIP8a, A3 or pIDEAE, at a concentration of
1 mg/ml in PBS-T at 4 1C overnight. AP-conjugated secondary
antibodies (rabbit anti-mouse IgG (Abcam), goat anti-mouse IgG
(Southern Biotech) or goat anti-rabbit IgG (Sigma-Aldrich)),
respectively, at a concentration of 2 mg/ml in PBS-T and AP
Conjugate Substrate Kit (Bio-Rad Labs, Hercules, CA, USA) were
used to visualize the bands.
Indirect ELISA for determination of sCD89–IgA complex in serum
High binding 96-well microtiter plates (Costar, Corning, New York,
USA) were coated with monoclonal mouse anti-human CD89
(A3; Abcam) at a concentration of 1 mg/ml. After overnight
incubation in a moist chamber at 4 1C the wells were blocked with
5% gelatin from cold water fish skin (Sigma-Aldrich) in PBS and
washed with PBS-T (Sigma-Aldrich). The serum samples from IgAN
patients, controls and reference serum (a patient sample with high
levels of sCD89) were diluted in PBS-T-1% fish gelatin in two
dilutions (1:10 and 1:1000) and in four 10-fold dilutions
(1:10–1:10,000), respectively. After 2 h of incubation at 37 1C in a
moist chamber, plates were washed and rabbit anti-human IgA
conjugated to AP (Dako) diluted 1:1000 in PBS-T-1% fish gelatin
was incubated in the plates for 2 h at 37 1C in a moist chamber. After
washing, the reaction was developed with AP substrate (Sigma-
Aldrich) in 1M diethanolamine buffer, pH 9.8, containing 1mM
MgCl2. Absorbance was read as optical density at 405 nm in a
Multiscan MS spectrophotometer (Labsystems, Helsinki, Finland)
after an appropriate time. Results are expressed as percent of the
reference.
Selection of genetic markers
The FCAR gene in the HapMap database represents a sequence on
chromosome 19q13.4 (OMIM 147045) with five known exons. After
initial selection of seven SNPs, five were tested in this study because
of the availability of reproducible assays: three SNPs in the intron 2
(rs11084377, rs4806605, rs10402324), one SNP in the intron 3 and
one in the exon 5. More detailed information on selected SNPs with
the minor allele frequencies is presented in Table 3.
DNA and genotyping
DNA was extracted from EDTA blood samples (5–10ml) by ‘salting
out’ method as described elsewhere.16 To identify all five investigated
SNPs of the FCAR gene (rs11084377, rs4806605, rs10402324,
rs1865097 and 16986050), TaqMan allelic discrimination assay
(Applied Biosystems, Foster City, USA) was used (see detailed
information in Table 3). Genotyping was performed according to a
standard protocol in 384-well plates with 10 ng of DNA per sample.
PCR was run in GeneAmp PCR System 9700 (Applied Biosystems)
and the fluorescent signals from the hybridization probes were
detected using a 7900 Sequence Detector (Applied Biosystems).
All analyzed markers were in Hardy–Weinberg equilibrium.
Positive rates of genotype detection were 99.9% for rs4806605,
Table 3 | Polymorphisms of the FCAR gene in IgAN patients
SNP Position in the gene structure Chromosome position Alleles Heterozygosity from NCBI MAFa ABI assay
rs11084377 Intron 2 60078702 A/G 0.429 0.294 C___1478510_10
rs4806605 Intron 2 60081476 C/T NA 0.194 C___27977742_10
rs10402324 Intron 2 60088425 A/G 0.408 0.342 C___7841644_10
rs1865097 Intron 3 60089029 A/G 0.431 0.343 C___7841632_10
rs16986050 Exon 5 60092982 A/G 0.273 0.183 C__25472878_10
Abbreviations: IgAN, immunoglobulin A nephropathy; MAF, minor allele frequency; NA, not available; NCBI, National Center for Biotechnology Information; SNP, single
nucleotide polymorphism.
aMAF from this study.
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99.4% for rs10402324, 99.6% for rs1865097, 97.8% for rs11084377
and 97.2% for rs16986050. A limited number of DNAs was
reanalyzed to perform quality control for genotyping robustness
with 499% reproducibility.
Statistical analysis
Mann–Whitney or Kruskal–Wallis Tests were used to test for
differences in the levels of sCD89 complex in patient and control
plasma, the sCD89 complex levels in individuals with different
genotypes and the severity of IgAN in different groups. To assess
genotype, allele and haplotype frequencies Pearson w2 and/or
Fisher’s Exact Tests were performed when appropriate, using SPSS
17.0 Software. Haplotype analysis was carried out using Haplo-
View.17 Power calculation was performed for two-tail or one-tail
tests when appropriate for 5% threshold of significance.
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